News
Adjuvant HER2/neu peptide cancer vaccines in breast cancer
Active cancer/peptide cancer immunotherapy remains an exciting and rapidly advancing field in oncology. Peptide cancer vaccines are an attractive therapeutic option as...
Research Insight
Landmark study confirms complexity and informs the next stages of research
The largest population genome sequencing effort to date is published today in Nature. A series of papers describing resources and application of the data...
Press Releases
Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission
European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use...
Press Releases
Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cance
European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use...
Press Releases
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients...
The primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin...
News
Pfizer Completes Acquisition of Hospira
Ian Read, chairman and chief executive officer, Pfizer Said, We are pleased that Hospira, the world’s leading provider of injectable drugs and infusion technologies...
Press Releases
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
Submission based on positive results of the landmark, global Phase 3 study, CheckMate -057 evaluating overall survival versus standard of care in non-squamous non-small...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read